Alnylam Pharmaceuticals, Inc. (LON:0HD2)
London · Delayed Price · Currency is GBP · Price in USD 435.57
-2.30 (-0.53%)
At close: Nov 7, 2025
Alnylam Pharmaceuticals Employees
Alnylam Pharmaceuticals had 2,230 employees as of December 31, 2024. The number of employees increased by 130 or 6.19% compared to the previous year.
Employees
2,230
Change (1Y)
130
Growth (1Y)
6.19%
Revenue / Employee
1.07M GBP
Profits / Employee
14.53K GBP
Market Cap
44.42B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2,230 | 130 | 6.19% |
| Dec 31, 2023 | 2,100 | 98 | 4.90% |
| Dec 31, 2022 | 2,002 | 337 | 20.24% |
| Dec 31, 2021 | 1,665 | 212 | 14.59% |
| Dec 31, 2020 | 1,453 | 130 | 9.83% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| Spire Healthcare Group | 15,703 |
| ConvaTec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| Genus | 3,190 |
Alnylam Pharmaceuticals News
- 16 hours ago - New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM - Business Wire
- 1 day ago - Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today - Benzinga
- 2 days ago - What Does the Market Think About Alnylam Pharmaceuticals Inc? - Benzinga
- 4 days ago - American Century Focused Dynamic Growth Fund Q3 2025 Performance Contributors And Detractors - Seeking Alpha
- 5 days ago - Royalty Pharma acquires royalty interest in Alnylam’s AMVUTTRA for $310M - Seeking Alpha
- 5 days ago - Alnylam to Webcast Presentations at Upcoming November Investor Conferences - Business Wire
- 5 days ago - Royalty Pharma (RPRX) Secures $310 Million Royalty Interest in Alnylam's AMVUTTRA - GuruFocus
- 5 days ago - Biotech is back. Here's why these rallying stocks belong in your portfolio now. - Market Watch